Skip to main content
SpringerLink
Log in

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: Current Status

  • Review
  • Published:
Archivum Immunologiae et Therapiae Experimentalis Aims and scope

Abstract

Hematopoietic cell transplantation (HCT) offers potentially curative therapy for patients with myelodysplastic syndrome (MDS). However, as the majority of patients with MDS is in the 7th or 8th decade of life, only few of these patients were transplanted following high-dose conditioning regimens. The development of reduced-intensity conditioning has allowed to apply HCT also to older patients and those with clinically relevant comorbid conditions. Dependent upon disease status and the type of clonal chromosomal abnormalities present at the time of HCT, some 25–75% of patients will be cured of their disease and survive long term. Recent results with HLA-matched unrelated donors are comparable to those with HLA genotypically identical siblings. The increasing use of cord blood and HLA-haploidentical donors is expected to make HCT available to a growing number of patients. However, post-transplant relapse and graft-versus-host disease remain problems requiring further instigations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Al-Ali HK, Brand R, van Biezen A et al (2007) A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 21:1945–1951

    PubMed  CAS  Google Scholar 

  • Alessandrino EP, Della Porta MG, Bacigalupo A et al (2008) WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 112:895–902

    PubMed  CAS  Google Scholar 

  • Alyea EP, Kim HT, Ho V et al (2006) Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 12:1047–1055

    PubMed  Google Scholar 

  • Armand P, Kim HT, Cutler CS et al (2007a) Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109:4586–4588

    PubMed  CAS  Google Scholar 

  • Armand P, Kim HT, DeAngelo DJ et al (2007b) Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 13:655–664

    PubMed  CAS  Google Scholar 

  • Armand P, Kim HT, Cutler CS et al (2008) A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 14:28–35

    PubMed  CAS  Google Scholar 

  • Armand P, Deeg HJ, Kim HT et al (2010) Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. Bone Marrow Transplant 45:877–885

    PubMed  CAS  Google Scholar 

  • Aversa F (2008) Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States (Review). Bone Marrow Transplant 41:473–481

    PubMed  CAS  Google Scholar 

  • Bacher U, Zander AR, Haferlach T et al (2008) Minimal residual disease diagnostics in myeloid malignancies in the post transplant period (Review). Bone Marrow Transplant 42:145–157

    PubMed  CAS  Google Scholar 

  • Barker JN, Weisdorf DJ, Defor TE et al (2005) Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105:1343–1347

    PubMed  CAS  Google Scholar 

  • Baron F, Sandmaier BM (2005) Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Curr Opin Hematol 12:435–443

    PubMed  Google Scholar 

  • Bartenstein M, Deeg HJ (2010) Hematopoietic stem cell transplantation for MDS. Hematol Oncol Clin North Am 24:407–422

    PubMed  Google Scholar 

  • Beelen DW, Trenschel R, Casper J et al (2005) Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 35:233–241

    PubMed  CAS  Google Scholar 

  • Beran M (2000) Intensive chemotherapy for patients with high-risk myelodysplastic syndrome (Review). Int J Hematol 72:139–150

    PubMed  CAS  Google Scholar 

  • Breccia M, Cannella L, Stefanizzi C et al (2009) WPSS versus simplified myelodysplastic syndrome risk score: which is the best tool for prediction of survival in myelodysplastic patients? Leuk Res 33:e93–e94

    PubMed  Google Scholar 

  • Brunstein CG, Weisdorf DJ (2009) Future of cord blood for oncology uses (Review). Bone Marrow Transplant 44:699–707

    PubMed  CAS  Google Scholar 

  • Brunstein CG, Gutman JA, Weisdorf DJ et al (2010) Allogeneic hematopoietic cell transplantation for hematological malignancy: relative risks and benefits of double umbilical cord blood. Blood 116:4693–4699

    PubMed  CAS  Google Scholar 

  • Busca A, Falda M, Manzini P et al (2010) Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. Biol Blood Marrow Transplant 16:115–122

    PubMed  CAS  Google Scholar 

  • Campregher PV, Gooley T, Scott BL et al (2007) Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 40:965–971

    PubMed  CAS  Google Scholar 

  • Casper J, Wolff D, Knauf W et al (2010) Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol 28:3344–3351

    PubMed  CAS  Google Scholar 

  • Castro-Malaspina H, Harris RE, Gajewski J et al (2002) Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99:1943–1951

    PubMed  CAS  Google Scholar 

  • Cazzola M, Della Porta MG, Malcovati L (2008) Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes (Review). Hematology Am Soc Hematol Educ Program 2008:166–175

    Google Scholar 

  • Chang C, Storer BE, Scott BL et al (2007) Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 110:1379–1387

    PubMed  CAS  Google Scholar 

  • Cutler CS, Lee SJ, Greenberg P et al (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104:579–585

    PubMed  CAS  Google Scholar 

  • de Lima M, Giralt S (2006) Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome (Review). Semin Hematol 43:107–117

    PubMed  Google Scholar 

  • de Lima M, Anagnostopoulos A, Munsell M et al (2004a) Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104:865–872

    PubMed  Google Scholar 

  • de Lima M, Couriel D, Thall PF et al (2004b) Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104:857–864

    PubMed  Google Scholar 

  • de Lima M, Giralt S, Thall PF et al (2010) Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 116:5420–5431

    PubMed  Google Scholar 

  • De Padua SL, de Lima M, Kantarjian H et al (2009) Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43:839–843

    Google Scholar 

  • De Roos AJ, Deeg HJ, Onstad L et al (2010) Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005–2006. Am J Hematol 85:765–770

    PubMed  Google Scholar 

  • de Witte T, Hermans J, Vossen J et al (2000) Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110:620–630

    PubMed  Google Scholar 

  • de Witte T, Brand R, van Biezen A et al (2009) Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br J Haematol 146:627–636

    PubMed  Google Scholar 

  • Deeg HJ (2009a) Hematopoietic cell transplantation for myelodysplastic syndrome and myeloproliferative disorders. In: Appelbaum FR, Forman SJ, Negrin RS et al (eds) Thomas’ hematopoietic cell transplantation. Wiley-Blackwell, Oxford, pp 827–844

    Google Scholar 

  • Deeg HJ (2009b) Transplant conditioning regimens: can we say it better? (Editorial). Biol Blood Marrow Transplant 15:653–655

    PubMed  Google Scholar 

  • Deeg HJ, Sandmaier BM (2010) Who is fit for allogeneic transplantation? Blood 116:4762–4770

    PubMed  CAS  Google Scholar 

  • Deeg HJ, Storer B, Slattery JT et al (2002) Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100:1201–1207

    PubMed  CAS  Google Scholar 

  • Deeg HJ, Maris MB, Scott BL et al (2006) Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia 20:1701–1705

    PubMed  CAS  Google Scholar 

  • Delaney C, Gutman JA, Appelbaum FR (2009) Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications (Review). Br J Haematol 147:207–216

    PubMed  CAS  Google Scholar 

  • Depil S, Deconinck E, Milpied N et al (2004) Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplant 33:531–534

    PubMed  CAS  Google Scholar 

  • Diez-Campelo M, Perez-Simon JA, Perez J et al (2009) Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. Am J Hematol 84:149–152

    PubMed  Google Scholar 

  • Farina L, Bruno B, Patriarca F et al (2009) The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia 23:1131–1138

    PubMed  CAS  Google Scholar 

  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232

    PubMed  CAS  Google Scholar 

  • Gattermann N (2009) The treatment of secondary hemochromatosis. Dtsch Arztebl Int 106:499–504

    PubMed  Google Scholar 

  • Gooley TA, Chien JW, Pergam SA et al (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363:2091–2101

    PubMed  CAS  Google Scholar 

  • Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088 [erratum appears in Blood 1998 91:1100]

    PubMed  CAS  Google Scholar 

  • Greenberg PL, Baer MR, Bennett JM et al (2006) Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw 4:58–77 [erratum appears in J Natl Compr Canc Netw 2006 Mar 4(3):table of contents Note: dosage error in text]

    PubMed  CAS  Google Scholar 

  • Guardiola P, Runde V, Bacigalupo A et al (2002) Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 99:4370–4378

    PubMed  CAS  Google Scholar 

  • Guilfoyle R, Demers A, Bredeson C et al (2009) Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant 43:133–139

    PubMed  CAS  Google Scholar 

  • Hamblin TJ (2002) Epidemiology of the myelodysplastic syndromes. In: Bennett JM (ed) The myelodysplastic syndromes: pathobiology and clinical management. Marcel Dekker, Inc, New York, pp 15–27

    Google Scholar 

  • Harrison SJ, Cook G, Nibbs RJ et al (2006) Immunotherapy of multiple myeloma: the start of a long and tortuous journey (Review). Expert Rev Anticancer Ther 6:1769–1785

    PubMed  CAS  Google Scholar 

  • Kang Y, Chao NJ, Aversa F (2008) Unmanipulated or CD34 selected haplotype mismatched transplants (Review). Curr Opin Hematol 15:561–567

    PubMed  CAS  Google Scholar 

  • Kantarjian H, O’Brien S, Ravandi F et al (2008) Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113:1351–1361

    PubMed  CAS  Google Scholar 

  • Kasamon YL, Luznik L, Leffell MS et al (2010) Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 16:482–489

    PubMed  CAS  Google Scholar 

  • Kataoka K, Nannya Y, Hangaishi A et al (2009) Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15:195–204

    PubMed  Google Scholar 

  • Kataoka K, Nannya Y, Ueda K et al (2010) Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study. Bone Marrow Transplant 45:513–520

    PubMed  CAS  Google Scholar 

  • Kawase T, Matsuo K, Kashiwase K et al (2009) HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood 113:2851–2858

    PubMed  CAS  Google Scholar 

  • Kelly SS, Sola CB, de Lima M et al (2009) Ex vivo expansion of cord blood (Review). Bone Marrow Transplant 44:673–681

    PubMed  CAS  Google Scholar 

  • Kindwall-Keller T, Isola LM (2009) The evolution of hematopoietic SCT in myelodysplastic syndrome (Review). Bone Marrow Transplant 43:597–609

    PubMed  CAS  Google Scholar 

  • Koh LP, Chao NJ (2004) Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens (Review). Biol Blood Marrow Transplant 10:1–22

    PubMed  Google Scholar 

  • Laport GG, Sandmaier BM, Storer BE et al (2008) Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 14:246–255

    PubMed  Google Scholar 

  • Lee JW, Kang HJ, Kim EK et al (2009) Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplant 44:793–797

    PubMed  CAS  Google Scholar 

  • Lee JH, Lee JH, Lim SN et al (2010) Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. Bone Marrow Transplant 45:450–457

    PubMed  Google Scholar 

  • Lim ZY, Ho AY, Ingram W et al (2006) Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol 135:201–209

    PubMed  Google Scholar 

  • Lim ZY, Pearce L, Ho AY et al (2007) Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol 138:517–526

    PubMed  CAS  Google Scholar 

  • Litzow MR, Tarima S, Perez WS et al (2010) Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 115:1850–1857

    PubMed  CAS  Google Scholar 

  • Luznik L, O’Donnell PV, Symons HJ et al (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 14:641–650

    PubMed  CAS  Google Scholar 

  • Mahindra A, Bolwell B, Sobecks R et al (2009) Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 146:310–316

    PubMed  CAS  Google Scholar 

  • Malcovati L, Germing U, Kuendgen A et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503–3510

    PubMed  Google Scholar 

  • Maradei SC, Maiolino A, de Azevedo AM et al (2009) Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 114:1270–1275

    PubMed  CAS  Google Scholar 

  • Marcondes M, Deeg HJ (2008) Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom? Best Pract Res Clin Haematol 21:67–77

    PubMed  CAS  Google Scholar 

  • Maris MB, Sandmaier BM, Storer BE et al (2004) Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104:3535–3542

    PubMed  CAS  Google Scholar 

  • Martino R, Iacobelli S, Brand R et al (2006) Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108:836–846

    PubMed  CAS  Google Scholar 

  • Michalek J, Collins RH, Durrani HP et al (2003) Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci USA 100:1180–1184

    PubMed  CAS  Google Scholar 

  • Mills KI, Kohlmann A, Williams PM et al (2009) Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 114:1063–1072

    PubMed  CAS  Google Scholar 

  • Nachtkamp K, Kundgen A, Strupp C et al (2009) Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res 33:1024–1028

    PubMed  CAS  Google Scholar 

  • Nakai K, Kanda Y, Fukuhara S et al (2005) Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 19:396–401

    PubMed  CAS  Google Scholar 

  • Nemecek ER, Guthrie KA, Sorror ML et al (2011) Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant 17:341–350

    PubMed  CAS  Google Scholar 

  • O’Donnell P, Luznik L, Symons H (2006) Favorable outcome of patients with relapsed Hodgkin lymphoma (HL) after nonmyeloablative hematopoietic cell transplantation (NM-HCT) using related haploidentical donors. Blood 108(Part 1):894a–895a #3135 (Abstract)

    Google Scholar 

  • O’Donnell PV, Harrington E, Gooley TA et al (2010) Cyclophosphamide-induced tolerance following bone marrow transplantation from haploidentical donors. Haematologica Edición Española 95(Extra 1):266–271

    Google Scholar 

  • Oliansky DM, Antin JH, Bennett JM et al (2009) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant 15:137–172

    PubMed  Google Scholar 

  • Ooi J (2006) The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome. Leuk Lymphoma 47:599–602

    PubMed  Google Scholar 

  • Ooi J, Iseki T, Takahashi S et al (2003) Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 101:4711–4713

    PubMed  CAS  Google Scholar 

  • Parimon T, Au DH, Martin PJ et al (2006) A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 144:407–414

    PubMed  Google Scholar 

  • Petersdorf EW (2009) Hematopoietic cell transplantation from unrelated donors. In: Appelbaum FR, Forman SJ, Negrin RS et al (eds) Blume thomas’ hematopoietic cell transplantation. Wiley-Blackwell, Oxford, pp 675–691

    Google Scholar 

  • Pidala J, Anasetti C, Kharfan-Dabaja MA et al (2009a) Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 15:1415–1421

    PubMed  Google Scholar 

  • Pidala J, Kim J, Field T et al (2009b) Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 15:1116–1121

    PubMed  CAS  Google Scholar 

  • Ramakrishnan A, Deeg HJ (2008) Allogeneic hematopoietic cell transplantation for patients with myelodysplastic syndrome and myeloproliferative disorders. In: Soiffer RJ (ed) Hematopoietic stem cell transplantation. Humana Press, Totowa, pp 167–182

    Google Scholar 

  • Rizzieri DA, Koh LP, Long GD et al (2007) Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 25:690–697

    PubMed  CAS  Google Scholar 

  • Rocha V, Gluckman E (2009) Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol 147:262–274

    PubMed  CAS  Google Scholar 

  • Rocha V, Locatelli F (2008) Searching for alternative hematopoietic stem cell donors for pediatric patients (Review). Bone Marrow Transplant 41:207–214

    PubMed  CAS  Google Scholar 

  • Samuelson S, Sandmaier BM, Heslop HE et al (2011) Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60–78 years of age. Br J Haematol 153:76–82

    PubMed  Google Scholar 

  • Sato A, Ooi J, Takahashi S et al (2011) Unrelated cord blood transplantation after myeloablative conditioning in adults with advanced myelodysplastic syndromes. Bone Marrow Transplant 46:257–261

    PubMed  CAS  Google Scholar 

  • Scott B, Deeg HJ (2006) Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders. Best Pract Res Clin Haematol 19:519–522

    PubMed  Google Scholar 

  • Scott BL, Storer B, Loken M et al (2005) Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 11:65–73

    PubMed  Google Scholar 

  • Scott BL, Sandmaier BM, Storer B et al (2006) Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20:128–135

    PubMed  CAS  Google Scholar 

  • Scott BL, Storer BE, Greene JE et al (2007) Marrow fibrosis as a risk factor for post-transplant outcome in patients with advanced MDS or AML with multilineage dysplasia. Biol Blood Marrow Transplant 13:345–354

    PubMed  Google Scholar 

  • Scott BL, Wells DA, Loken MR et al (2008) Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 112:2681–2686

    PubMed  CAS  Google Scholar 

  • Shaw BE, Mufti GJ, Mackinnon S et al (2008) Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant 42:783–789

    PubMed  CAS  Google Scholar 

  • Sierra J, Pérez WS, Rozman C et al (2002) Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100:1997–2004

    PubMed  CAS  Google Scholar 

  • Sorror M, Maris M, Baron F (2004) A modified hematopoietic cell transplantation (HCT)-specific co-morbidity index. Blood 104(Part 1):324a–325a #1146 (Abstract)

    Google Scholar 

  • Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912–2919

    PubMed  CAS  Google Scholar 

  • Sorror M, Storer B, Sandmaier BM et al (2008) Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 112:1992–2001

    PubMed  Google Scholar 

  • Spitzer TR (2005) Haploidentical stem cell transplantation: the always present but overlooked donor. Hematol Am Soc Hematol Educ Program 2005:390–395

    Google Scholar 

  • Steensma DP, Bennett JM (2006) The myelodysplastic syndromes: diagnosis and treatment (Review). Mayo Clin Proc 81:104–130

    PubMed  Google Scholar 

  • Stetler-Stevenson M, Arthur DC, Jabbour N et al (2001) Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98:979–987

    PubMed  CAS  Google Scholar 

  • Strasser SI, Kowdley KV, Sale GE et al (1998) Iron overload in bone marrow transplant recipients. Bone Marrow Transplant 22:167–173

    PubMed  CAS  Google Scholar 

  • Sucak GT, Yegin ZA, Ozkurt ZN et al (2008) The role of liver biopsy in the workup of liver dysfunction late after SCT: is the role of iron overload underestimated? Bone Marrow Transplant 42:461–467

    PubMed  CAS  Google Scholar 

  • Valcarcel D, Martino R (2007) Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia (Review). Curr Opin Oncol 19:660–666

    PubMed  Google Scholar 

  • Vaughn J, Storer B, Mielcarek M et al (2010) Treatment of recurrent or persistent AML/MDS after allogeneic hematopoietic cell transplantation with azacitidine. Blood 116:551 #1288 (Abstract)

    Google Scholar 

  • Warlick ED, O’Donnell PV, Borowitz M et al (2008) Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res 32:1439–1447

    PubMed  CAS  Google Scholar 

  • Warlick ED, Cioc A, DeFor T et al (2009) Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 15:30–38

    PubMed  Google Scholar 

  • Wells DA, Benesch M, Loken MR et al (2003) Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hemopoietic stem cell transplantation. Blood 102:394–403

    PubMed  CAS  Google Scholar 

  • Welniak LA, Blazar BR, Murphy WJ (2007) Immunobiology of allogeneic hematopoietic stem cell transplantation (Review). Annu Rev Immunol 25:139–170

    PubMed  CAS  Google Scholar 

  • Yakoub-Agha I, de La Salmonière P, Ribaud P et al (2000) Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of bone marrow transplantation. J Clin Oncol 18:963–971

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported in part by NIH Grant P30HL036444, Bethesda, MD, USA. We thank Helen Crawford and Bonnie Larson for help with manuscript preparation.

Author information

Authors and Affiliations

  1. Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1-100, Seattle, WA, 98109-1024, USA

    H. Joachim Deeg & Matthias Bartenstein

  2. University of Washington School of Medicine, Seattle, WA, USA

    H. Joachim Deeg

Authors
  1. H. Joachim Deeg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthias Bartenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Joachim Deeg.

About this article

Cite this article

Deeg, H.J., Bartenstein, M. Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: Current Status. Arch. Immunol. Ther. Exp. 60, 31–41 (2012). https://doi.org/10.1007/s00005-011-0152-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00005-011-0152-z

Keywords

Search

Navigation